UBS Group
CPHR

UBS Group’s Cipher Pharmaceuticals Inc. CPHR Stock Holding History

UBS Group’s Portfolio CPHR Stock Details CPHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-149
Closed -$1K – 8222
2016
Q2 		$1K Sell
149
-1,295
-90% -$7.38K ﹤0.01% 7632
2016
Q1 		$7K Buy
+1,444
New +$6.34K ﹤0.01% 6890
2015
Q4 		– Sell
-422
Closed -$2K – 8790
2015
Q3 		$2K Sell
422
-1,052
-71% -$7.31K ﹤0.01% 8147
2015
Q2 		$13K Buy
1,474
+763
+107% +$7.6K ﹤0.01% 7285
2015
Q1 		$6K Buy
+711
New +$8.93K ﹤0.01% 8051

Other funds holding CPHR

MBI
Montrusco Bolton Investments Montreal, Quebec, Canada $6.46B AUM 26.7% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return
TAM
Taylor Asset Management Toronto, Ontario, Canada $154M AUM 10.32% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NEI
Northwest & Ethical Investments Toronto, Ontario, Canada $4.32B AUM 23.26% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's CPHR Position: Q3 2016 in Review

UBS Group sold out of Cipher Pharmaceuticals Inc. (CPHR) in Q3 2016, closing a stake of 149 shares — an estimated $1K sold.

UBS Group first reported a position in CPHR in Q1 2015 and held it in 5 quarters. The position peaked at $13K in Q2 2015. 18 funds tracked by Wall St. Rank hold CPHR as of Q3 2016.

  • UBS Group reported no remaining Cipher Pharmaceuticals Inc. position as of Q3 2016 after selling out during the quarter.
  • UBS Group sold 149 Cipher Pharmaceuticals Inc. shares in Q3 2016, an estimated $1K.
  • UBS Group first reported a position in Cipher Pharmaceuticals Inc. in Q1 2015 and held it in 5 quarters.
  • UBS Group's Cipher Pharmaceuticals Inc. position peaked at $13K in Q2 2015.
  • 18 funds tracked by Wall St. Rank held Cipher Pharmaceuticals Inc. as of Q3 2016.

Based on UBS Group's 13F filing for Q3 2016, filed 14 Nov 2016.